Galderma's Chief Science Officer has positioned early skin-care intervention as the clinical foundation for managing GLP-1-related facial changes—a shift that reframes the aesthetic practice's role from corrective to preventive. The guidance emphasizes establishing a robust skincare regimen before patients initiate GLP-1 therapy, rather than waiting for volume loss to manifest and then reaching for fillers.
Injectables
Galderma Chief: Start GLP-1 Patients on Skin Care First
Galderma's CSO outlines preventive protocol for GLP-1-induced facial volume loss before injectable correction.
Start GLP-1 patients on skin care before injectable correction, not after volume loss.
This approach acknowledges the mechanism: rapid weight loss from GLP-1 agonists accelerates collagen and elastin breakdown, creating a tissue-quality deficit that fillers alone cannot fully address. By priming skin barrier function and elasticity upfront, practices can reduce the volume of filler required and improve clinical outcomes. The protocol also positions practices as advisors on systemic health impacts—a value-add that differentiates from commodity filler injection. For owners, this signals Galderma's confidence in its skincare portfolio and hints at bundled reimbursement or loyalty incentives tied to integrated protocols.
Source: original report ↗
Free alerts
Free: recall & rule-change alerts for your practice.
Get the recalls and state-law changes that hit your treatment room, in your inbox — free. Unsubscribe in one click.
Free · weekly · unsubscribe anytime. Privacy.
Stay three moves ahead of every practice in your market.
Knowing it happened is table stakes. Inside MedSpa Pro hands you the play — what each move means for your margins, your license, and your patients, and exactly what to do about it — in a two-minute brief, twice a week. The owners who read it never get blindsided.
Get the edge · $20/moJoin the owners who run ahead of the industry. Cancel anytime, one click.